Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsProtocol groupAggressive LymphomasHodgkin LymphomaIndolent LymphomasradiotherapyDiseaseHodgkin LymphomaMantle Cell LymphomaNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, Follicular Grade I-IIIaNHL, B-Cell Type, Follicular grade IIIbNHL, B-Cell Type, IndolentNHL, T-Cell Type, Peripheral, UnspecifiedSubgroupNodular lymphocyte-predominant (NLPHL)unfitICD10C81.-C82.-C82.7C82.9C83.1C83.3C84.4MeSHHodgkin DiseaseLymphoma, Large B-Cell, DiffuseLymphoma, Mantle-CellLymphoma, T-Cell, PeripheralSequenceBRNT1.8/DCRB375, Hodgkin, C1-12 (PID2364) -|- BRNT1.8/DCRB375 - BRNT1.8, C1-16 (PID2365).BRNT1.8/NIVO3, Hodgkin, C1 (PID1903) -|- C2-4 (PID1904)CheckMate 205: NIVO240, Hodgkin, A (PID1374) -|- N-AVD (NIVO240/DOXO25/VNBL6/DCRB375), B (PID1375)NIVAHL Arm B: NIVO240, Hodgkin, A (PID1374) -|- N-AVD (PID1970) -|- AVD (PID257)PAED EuroNet-PHL-C2, Hodgkin, TL-1PAED EuroNet-PHL-C2, Hodgkin, TL-2PAED EuroNet-PHL-C2, Hodgkin, TL-3PEMB200, Hodgkin, A (PID1969) -|- AVD (DOXO25/VNBL6/DCRB375), B (PID1962)PEMB200/ICE (ETOP100/CRBP5/IFOS5), Hodgkin, C1-2 (PID2691) -|- PEMB200, C3 (PID2692)PEMB200/LDOX15/GEMC1000/VINO20, Hodgkin (PID2024) -|- BRNT1.8, maint. (PID849)RITU375, Hodgkin, C1-4 (PID2360) -|- RITU375, maint., C5-8 (PID2361)ChemotherapyChemo-substanceBendamustineBleomycinBrentuximab vedotinCarboplatinCarmustineCisplatinCyclophosphamideCytarabineDacarbazineDexamethasoneDoxorubicinDoxorubicin liposomalEtoposideGemcitabineIfosfamideMelphalanMethylprednisoloneNivolumabOxaliplatinPembrolizumabPrednisoloneProcarbazineRituximabVinblastineVincristineVinorelbineChemo-substanceBendamustineBleomycinBrentuximab vedotinCarboplatinCarmustineCisplatinCyclophosphamideCytarabineDacarbazineDexamethasoneDoxorubicinDoxorubicin liposomalEtoposideGemcitabineIfosfamideMelphalanMethylprednisoloneNivolumabOxaliplatinPembrolizumabPrednisoloneProcarbazineRituximabVinblastineVincristineVinorelbineChemo-substanceBendamustineBleomycinBrentuximab vedotinCarboplatinCarmustineCisplatinCyclophosphamideCytarabineDacarbazineDexamethasoneDoxorubicinDoxorubicin liposomalEtoposideGemcitabineIfosfamideMelphalanMethylprednisoloneNivolumabOxaliplatinPembrolizumabPrednisoloneProcarbazineRituximabVinblastineVincristineVinorelbineChemo-substanceBendamustineBleomycinBrentuximab vedotinCarboplatinCarmustineCisplatinCyclophosphamideCytarabineDacarbazineDexamethasoneDoxorubicinDoxorubicin liposomalEtoposideGemcitabineIfosfamideMelphalanMethylprednisoloneNivolumabOxaliplatinPembrolizumabPrednisoloneProcarbazineRituximabVinblastineVincristineVinorelbineNo. Substances1234567 RadiotherapySupportive therapySupportive substanceAciclovirAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFilgrastimFosaprepitantGranisetronMagnesiumMagnesium sulfateMesnaParacetamolPegfilgrastimPotassium chloridePrednisoloneSupportive substanceAciclovirAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFilgrastimFosaprepitantGranisetronMagnesiumMagnesium sulfateMesnaParacetamolPegfilgrastimPotassium chloridePrednisoloneSupportive substanceAciclovirAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFilgrastimFosaprepitantGranisetronMagnesiumMagnesium sulfateMesnaParacetamolPegfilgrastimPotassium chloridePrednisoloneSupportive substanceAciclovirAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFilgrastimFosaprepitantGranisetronMagnesiumMagnesium sulfateMesnaParacetamolPegfilgrastimPotassium chloridePrednisoloneNo. Substances123456789Protocol classificationTherapy classificationalternativecurrent standardStudy protocol, currentIntensityDose denseDose intensifiedhigh doseStandard doseTherapy indicationFirst lineRelapse therapySecond lineseveral possibleTherapy phaseInductionMaintenanceReinductionTherapy intentioncurativecurative or palliativepalliativeRisksAdrenal InsufficiencyAlopeciaAnemia Hb below 8g/dlAnemia Hb below 10g/dlArthalgiaAstheniaCardiotoxicityColitisConstipationDiarrheaDyspneaEdemaEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaGastrointestinal ToxicityHand-Foot SyndromeHeadacheHematuriaHepatotoxicityHyperglycemiaHypertensionHyperthyroidismHypocalcemiaHypokalemiaHypomagnesemiaHyponatremiaHypophosphatemiaHypotensionHypothyroidismIncrease AminotransferasesIncrease in lipaseInfectionsInfusion ReactionLeukopeniaLymphopeniaMucositisMyalgiasNephritisNephrotoxicityNeuropathyNeurotoxicityNeutropeniaOral MucositisPainParesthesiaPneumoniaPruritusPyrexiaRashSepsisThrombocytopenia below 50 000/µlUpper Respiratory Tract Infection only studiesPublicationAuthorAbali H Allen PBehringer KBorchmann PBryan LJBröckelmann PBöll BCencini EChen RCheson BDColwill RConnors JEichenauer DAEngert AFriedberg JW Gopal AGutierrez AHerrera AFHertzberg MSJosting AKumar AKörholz DLittle RLynch RCMoskowitz AJMoskowitz CO'Connor OAPrusila REIRamchandren RSantoro ATessoulin BWon YWYounes ADiseaseB-Non-Hodgkin-Lymphom/Hodgkin Lymphomfortgeschrittenes Hodgkin Lymphom, Stadium III-IV, Erstlinie, ECOG 0-2fortgeschrittenes klassisches Hodgkin Lymphom, Erstlinie, ECOG 0-1fortgeschrittenes oder early unfavorable Hodgkin Lymphom, Erstlinie, ECOG 0-1Hodgkin Lymphom, Erhaltung nach ASZT bei Patienten mit erhöhtem Rezidiv- oder Progressionsrisiko, ECOG 0-2Hodgkin Lymphom, Erstlinientherapie, >60 Jahre, ECOG 0-1Hodgkin Lymphom, NLPHL Stadium IA ohne RisikofaktorenHodgkin Lymphom, nodulär-lymphozytenprädominant (NLPHL)Hodgkin Lymphom, rezidiviert nach autologer Stammzelltransplantation, Ann Arbor II-IVHodgkin Lymphom, rezidiviert oder therapierefraktärHodgkin Lymphom, rezidiviert oder therapierefraktär, ECOG 0-3Hodgkin Lymphom, rezidiviert oder therapierefraktär, nach autologer SCT oder SCT ungeeignetHodgkin Lymphom, Stadium I-II, ErstlinieHodgkin Lymphom, Stadium IIb - IV, Erstlinie, 18-60 JahreHodgkin Lymphom, therapierefraktär oder rezidiviert, ECOG 0-1Hodgkin Lymphom, über 60 J., unfit, ECOG 0-3, ErstlinieHodgkin Lymphom Stadium IIb mit Risikofaktoren, Stadium III und IV, Erstlinie, 18-60 JahreHodgkin Lymphom Stadium I und II ohne RisikofaktorenHodgkin Lymphom Std. IIb mit Risikofaktoren, Std. III u IV, Erstlinie, 18-60 Jahreklassisches Hodgkin lymphom, early stage und unfavorable, ECOG 0-1klassisches Hodgkin Lymphom, Rezidiv nach ASZT und Brentuximab Vedotin, ECOG 0-1neudiagnostiziertes Hodgkin Lymphom, Ann Arbor stage IA-IIB, ECOG 0-2neu diagnostiziertes Hodgkin Lymphom, fortgeschritten, Alter 60-75, ECOG 0-2Neudiagnostiziertes Hodgkin Lymphom im Kindes- und JugendalterNHL, HL, Rezidiv, fehlende Remission nach kurativer ChemotherapieNodulär-lymphozytenprädominantes Hodgkin-Lymphom (NLPHL)Nodulär-lymphozytenprädominantes Hodgkin-Lymphom (NLPHL), therapierefraktär oder rezidiviert, ECOG 0-1Non-Hodgkin-Lymphom / Hodgkin Lymphomprimär refraktäres oder rezidiviertes Hodgkin Lymphom, ECOG 0-2refraktäres oder rezidivierendes Hodgkin Lymphom, ECOG 0-1refraktäres oder rezidiviertes Hodgkin Lymphom, für eine Transplantation geeignet, ECOG 0-1rezidivierendes oder refraktäres Hodgkin Lymphom, 18-65 Jahre, ECOG 0-2rezidivierendes oder refraktäres Non-Hodgkin-Lymphom, ECOG 0-2Rezidiviertes oder refraktäres Hodgkin Lymphom, ECOG 0-1Rezidiviertes oder refraktäres Hodgkin Lymphom nach Hochdosis Chemotherapie und ASZT, ECOG 0-1OriginAnderson Cancer Center, The University of Texas MD, HoustonCenter for Lymphoid Malignancies, Columbia University Medical Center-College of Physicians and Surgeons, New York, NY, USACity of Hope National Medical Center, Duarte, CanadaDepartment of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, ECHELON-1Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, ItalyDivision of Hematology and Oncology, Georgia Cancer Center at Augusta University, AugustaEmory University Winship Cancer Institute, Atlanta, GAEuropean Network-Paediatric Hodgkin’s LymphomaStudy Group (EuroNet-PHL)German-Speaking Myeloma Multicenter Group, GMMG-HD6, GHSG-HD21 German Hodgkin Study Group (GHSG) German Hodgkin Study Group (GHSG), University Hospital of Cologne, HD 13German Hodgkin Study Group NIVAHL TrialHaematology Unit, Azienda Ospedaliera Universitaria Senese and University of Siena, Siena, ItalyHanyang University College of Medicine, Seoul, South KoreaKlinik für Innere Medizin, Universität KölnKlinik I für Innere Medizin, Universitätsklinikum KölnLymphoma Research Foundation, New York, USA, ACCRU trialMedical Oncology Unit, Mersin University, Mersin, TurkeyMemorial Sloan-Kettering Cancer Center, New York, NY, USAMemorial Sloan Kettering Cancer Center, KEYNOTE-087 investigatorsMemorial Sloan Kettering Cancer Center, New YorkMemorial Sloan Kettering Cancer Center, New York, AETHERA trialMemorial Sloan Kettering Cancer Center, New York, USANantes Medical University, Nantes, FranceNational Cancer Institute, Bethesda, USAService of Hematology, Son Espases University Hospital, Palma de Mallorca, SpainUniversity Hospital Cologne and University Hospital Münster, GermanyUniversity of Oulu, Oulu, FinlandUniversity of Tennessee, Knoxville, TN, Checkmate 205University of Toronto Autologous Bone Marrow Transplant Program, Toronto Hospital, CanadaUniversity of Washington, Seattle, USAUniversity of Washington/Fred Hutchinson Cancer Research Center, Seattle, WAWestmead Hospital, Westmead, AustraliaWilmot Cancer Institute, University of Rochester, Rochester, NY, USAProtocols in Revision 45 protocols foundProtocols under revision.ABVD - Doxorubicin 25 / Bleomycin 10 / Vinblastine 6 / Dacarbazine 375, Hodgkin Lymphoma (PID472 V1.3)BEACOPP Basis, Hodgkin Lymphoma (PID474 V1.0)BEACOPP dosisescalated, Hodgkin Lymphoma (PID473 V1.2)Bendamustine 120, Hodgkin Lymphoma (PID2395 V1.0)Brentuximab Vedotin 1.8 / Bendamustine 90, Hodgkin Lymphoma (PID2363 V1.0)Brentuximab Vedotin 1.8 / Cyclophosphamide 1250 / Doxorubicin 40 / Etoposide 150 / Dacarbazine 250 / Dexamethasone 40, Hodgkin Lymphoma (PID962 V2.0)Brentuximab Vedotin 1.8 / Dacarbazine 375 - Brentuximab Vedotin 1.8, Hodgkin Lymphoma, Cycle 13-16 (PID2365 V1.0)Brentuximab Vedotin 1.8 / Dacarbazine 375, Hodgkin Lymphoma, Cycle 1-12 (PID2364 V1.0)Brentuximab Vedotin 1.8 / Nivolumab 3, Hodgkin Lymphoma (PID90 V2.0)Brentuximab Vedotin 1.8 / Nivolumab 3, Hodgkin Lymphoma, cycle 1 (PID1903 V1.0)Brentuximab Vedotin 1.8 / Nivolumab 3, Hodgkin Lymphoma, cycle 2-4 (PID1904 V1.0)Brentuximab Vedotin 1.8, maintenance, Hodgkin Lymphoma (PID849 V1.0)Brentuximab Vedotin 1.8, Hodgkin Lymphoma (PID475 V1.1)BV-ICE - Brentuximab Vedotin 1.5 / Etoposide 100 / Carboplatin 5 / Ifosfamide 5, Hodgkin Lymphoma (PID1902 V1.0)DHAC - Carboplatin 5 / Cytarabine 2000 / Dexamethasone 40, Non-Hodgkin Lymphoma / Hodgkin Lymphoma. (PID2346 V1.0)DHAP - Dexamethasone 40 / Cisplatin 100 / Cytarabine 2000, Hodgkin Lymphoma (PID1156 V1.1)Doxorubicin 25 / Vinblastine 6 / Dacarbazine 375 / Brentuximab Vedotin 1,2 / Radiation, Hodgkin Lymphoma (PID1951 V1.0)Doxorubicin 25 / Vinblastine 6 / Dacarbazine 375 / Brentuximab Vedotin 1,2, Hodgkin Lymphoma (PID587 V1.0)Doxorubicin 25 / Vinblastine 6 / Dacarbazine 375, Hodgkin Lymphoma (PID257 V1.0)Doxorubicin 25 / Vinblastine 6 / Dacarbazine 375, Hodgkin Lymphoma, Part B (PID1962 V1.0)ESHAOx - Etoposide 40 / Oxaliplatin 130 / Cytarabine 2000 / Methylprednisolone 500, Hodgkin Lymphoma (PID2347 V1.0)GemOx - Gemcitabine 1000 / Oxaliplatin 100, Hodgkin Lymphoma (PID2382 V1.0)ICE - Ifosfamide 1.33 / Carboplatin 5 / Etoposide 100, Hodgkin Lymphoma. (PID2380 V1.0)Ifosfamide 2 / Gemcitabine 800 / Vinorelbine 20 / Prednisolone 100, Hodgkin Lymphoma (PID70 V1.1)mini-BEAM - Carmustine 60 / Etoposide 75 / Cytarabine 100 / Melphalan 30, Hodgkin Lymphoma (PID2381 V1.0)Nivolumab 240 / Doxorubicin 25 / Vinblastine 6 / Dacarbazine 375, Hodgkin Lymphoma (PID1970 V1.1)Nivolumab 240 / Doxorubicin 25 / Vinblastine 6 / Dacarbazine 375, Hodgkin Lymphoma, Part B (PID1375 V1.2)Nivolumab 240, Hodgkin Lymphoma (PID844 V2.0)Nivolumab 240, Hodgkin Lymphoma, part A (PID1374 V1.0)PAED EuroNet-PHL-C2, OEPA, Hodgkin Lymphoma (PID1280 V1.0)Pembrolizumab 200 / Doxorubicin liposomal 15 / Gemcitabine 1000 / Vinorelbine 20, Hodgkin lymphoma (PID2024 V1.0)Pembrolizumab 200 / ICE (Etoposide 100 / Carboplatin 5 / Ifosfamide 5) - Pembrolizumab 200, Hodgkin Lymphoma, Cycle 3 (PID2692 V1.0)Pembrolizumab 200 / ICE (Etoposide 100 / Carboplatin 5 / Ifosfamide 5), Hodgkin Lymphoma, Cycle 1-2 (PID2691 V1.0)Pembrolizumab 200, Hodgkin Lymphoma (PID1264 V1.0)Pembrolizumab 200, Hodgkin Lymphoma, A (PID1969 V1.0)Pembrolizumab 400, Hodgkin Lymphoma (PID1269 V1.0)Prednisolone 40 / Vinblastine 6 / Doxorubicin 50 / Gemcitabine 1000, Hodgkin Lymphoma (PID1075 V1.0)R- Benda - Rituximab 375 / Bendamustine 120, Hodgkin Lymphoma (PID2405 V1.0)R-ABVD - Rituximab 375 / Doxorubicin 25 / Bleomycin 10 / Vinblastine 6 / Dacarbazine 375, Hodgkin Lymphoma (PID2396 V1.0)R-DHAC - Rituximab 375 / Carboplatin 5 / Cytarabine 2000 / Dexamethasone 40, B-Non-Hodgkin's Lymphoma/Hodgkin's Lymphoma (PID2345 V1.0)R-GDC - Rituximab 375 / Gemcitabine 1000 / Dexamethasone 40 / Carboplatin 5, diffuse large B-non-Hodgkin Lymphoma (PID1681 V1.0)R-ICE - Rituximab 375 / Etoposide 100 / Carboplatin 5 / Ifosfamide 1.67, Hodgkin Lymphoma (PID2383 V1.0)Rituximab 375, Hodgkin Lymphoma, maintenance, cycle 5-8 (PID2361 V1.0)Rituximab 375, Hodgkin Lymphoma, Cycle 1-4 (PID2360 V1.0)Vinblastine 6, Hodgkin Lymphoma (PID2331 V1.0)
